Publications by authors named "Mary Katherine Farmer"
Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study.
Désirée van der Heijde Lianne S Gensler Atul Deodhar Xenofon Baraliakos Denis Poddubnyy Mary Katherine Farmer
Ann Rheum Dis
May 2020
Article Synopsis
- Bimekizumab, a treatment that targets IL-17A and IL-17F, was tested in a phase IIb study to evaluate its effectiveness and safety in patients with active ankylosing spondylitis (AS).
- The study involved 303 participants who were randomly assigned to different doses of bimekizumab or a placebo, with the primary measure of success being the ASAS40 response after 12 weeks.
- Results showed that patients receiving bimekizumab had significantly better outcomes compared to placebo, with sustained benefits observed up to 48 weeks, alongside a manageable safety profile.